The fact is that if LP had settled for setting up the first CDMO (Cognate), NWBO would have had commercial production ability years ago. And would have had enough free cash to have run several Direct and combo trials.
But when she sold Cognate she decided it made more sense for NWBO to deal with the startup Advent that she owned.
If you think LP made a reasonable decision, then certainly nothing in criminal in that.
Some in the biotech space would think advancing the 2 lead products would have been a better use of funds.
Market Data 
Markets 
AI
